Summit Therapeutics (SMMT) Cash from Financing Activities (2019 - 2026)

Summit Therapeutics' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $3.8 million for Q1 2026.

• Quarterly Cash from Financing Activities fell 50.54% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $613.7 million (up 57.99% YoY) and the FY2025 annual result came in at $617.5 million, up 61.99% from the prior year.
• Cash from Financing Activities was $3.8 million for Q1 2026 at Summit Therapeutics, down from $573.8 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $573.8 million in Q4 2025 and bottomed at -$23.6 million in Q4 2024.
• A 5-year average of $106.8 million and a median of $16.4 million in 2022 frame the typical range for Cash from Financing Activities.
• Peak annual rise in Cash from Financing Activities reached 250365.0% in 2024, while the deepest fall reached 477.67% in 2024.
• Summit Therapeutics' Cash from Financing Activities stood at $520.1 million in 2022, then sank by 98.8% to $6.3 million in 2023, then sank by 477.67% to -$23.6 million in 2024, then jumped by 2530.21% to $573.8 million in 2025, then slumped by 99.34% to $3.8 million in 2026.
• Business Quant data shows SMMT's Cash from Financing Activities at $3.8 million in Q1 2026, $573.8 million in Q4 2025, and $33.8 million in Q3 2025.